- Home
- KFS vs ARMP Comparison
KFS vs ARMP Comparison
Compare KFS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KFS | ARMP |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.8M | 383.7M |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KFS | ARMP |
|---|---|---|
| Price | $10.72 | $8.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 53.2K | ★ 69.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $134,996,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.42 | N/A |
| 52 Week Low | $9.84 | $1.17 |
| 52 Week High | $16.80 | $14.98 |
Technical Indicators
Market Signals| Indicator | KFS | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.98 | 37.96 |
| Support Level | $10.00 | $7.43 |
| Resistance Level | $12.06 | $12.11 |
| Average True Range (ATR) | 0.53 | 1.32 |
| MACD | -0.02 | -0.23 |
| Stochastic Oscillator | 32.80 | 11.97 |
Price Performance
Historical ComparisonAbout KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The company generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.